共 24 条
- [2] Challenges in Assessing the Impact of the COVID-19 Pandemic on the Integrity and Interpretability of Clinical Trials [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2020, 12 (04): : 419 - 426
- [5] FDA (Food and Drug Administration), 2021, SPONS RESP SAF REP R
- [6] FDA (Food and Drug Administration), 2005, PLANS
- [7] FDA (Food and Drug Administration), 2005, PREM RISK ASS
- [8] FDA (Food and Drug Administration), DEV US RISK MIN ACT
- [9] FDA (Food and Drug Administration), 2021, MET RAND CONTR CLIN